Report
EUR 166.30 For Business Accounts Only

Moody's assigns Ba3 to Alkermes' sr. secured term loan; stable outlook

Rating Action: Moody's assigns Ba3 to Alkermes' sr. secured term loan; stable outlook. Global Credit Research- 24 Feb 2020. New York, February 24, 2020-- Moody's Investors Service assigned a Ba3 rating to the new senior secured term loan of Alkermes, Inc., a subsidiary of Alkermes plc.
Underlying
Alkermes Plc

Alkermes is a biopharmaceutical company. Co.'s products include: ARISTADA, which is an extended-release injectable suspension for the treatment of schizophrenia; VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence; INVEGA SUSTENNA/XEPLION, and RISPERDAL CONSTA, which is for the treatment of schizophrenia and for the treatment of schizoaffective disorder; AMPYRA/FAMPYRA, which is a treatment to improve walking in adults with multiple sclerosis; and BYDUREON is for the treatment of type 2 diabetes. Co.'s product candidate include Aripiprazole Lauroxil Two-Month Dose for the treatment of schizophrenia, among others.

Provider
Moody's Investors Service
Moody's Investors Service

Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:

  • 130 countries
    11,000 corporate issuers
    21,000 public finance issuers
    76,000 structured finance obligations



Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.



Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions. 

Other Reports on these Companies
Other Reports from Moody's Investors Service

ResearchPool Subscriptions

Get the most out of your insights

Get in touch